Day: December 23, 2020

MONROE TOWNSHIP, N.J., Dec. 23, 2020 (GLOBE NEWSWIRE) — Ocean Power Technologies, Inc. (“OPT” or “the Company”) (NASDAQ: OPTT), a leader in innovative and cost-effective ocean energy solutions, today announced that Clyde W. Hewlett, Diana G. Purcel, and Peter E. Slaiby were elected to its Board of Directors by the Company stockholders at the 2020 Annual General Meeting effective December 23, 2020.“We are excited to welcome Clyde, Diana, and Pete as new independent directors to the OPT board. These new directors bring valuable expertise in offshore energy, safety, and finance and governance, and join OPT at an exciting time. We have proven products and solutions ready for commercialization, a receptive marketplace, access to capital, and a dedicated and experienced team to continue innovations towards...

ROSEMONT, Ill., Dec. 23, 2020 (GLOBE NEWSWIRE) — Wintrust Financial Corporation (“Wintrust”) (Nasdaq: WTFC) today announced it will release its fourth quarter and year-to-date 2020 earnings results after the market closes on Wednesday, January 20, 2021 and host a conference call on Thursday, January 21, 2021 at 10:00 a.m. (CDT). Individuals interested in participating in the call should dial 877-363-5049 and enter Conference ID #9780585 or a simultaneous audio-only web cast may be accessed via the Company’s web site at http://www.wintrust.com, Investor Relations link.   An accompanying slide presentation for those participating in the call or listening via web cast will be available on the Company’s web site at http://www.wintrust.com, Investor Relations link.A replay of the audio-only webcast and an accompanying slide...

ATHENS, Greece, Dec. 23, 2020 (GLOBE NEWSWIRE) — TEN, Ltd (“TEN” or the “Company”) (NYSE: TNP) today announced 24-month charters extensions with profit sharing provisions for two product tankers to a major oil concern. Excluding options for an additional 12-month period at expiration of this fixture, the combined minimum revenues from these contracts are expected at around $20.0 million. Should the additional options get exercised, the total minimum revenues could surpass $32 million.“Following our stated policy, these charters to first-class counterparties provide earnings visibility and upside potential. This flexibility has become the cornerstone of our strategy over the years and has served the Company well in navigating smoothly the market cyclicality,” Mr. George Saroglou, Chief Operating Officer of TEN stated. “As we leave...

Data presented throughout 2020 have validated the potential of the PATrOL™ platform to develop highly targeted therapies that increase, decrease or change causal protein functionPlan to provide updates on development pipeline, including the myotonic dystrophy type 1 (DM1) and Huntington’s disease (HD) programs, at an R&D day in the first half of CY2021PITTSBURGH, Pa., Dec. 23, 2020 (GLOBE NEWSWIRE) — NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology company accelerating the genetic revolution using a new class of synthetic medicines, today reported its financial results for the fiscal year ended September 30, 2020.“Throughout 2020, we successfully executed against our development strategy, most notably with the generation of two very exciting datasets supporting our initial therapeutic...

Continuing to Serve Customers In-Store and OnlineMAHWAH, N.J., Dec. 23, 2020 (GLOBE NEWSWIRE) — ascena retail group, inc. (OTCMKTS: ASNAQ) and certain of its subsidiaries (collectively, “ascena” or the “Company”) today announced that it has completed the sale of the Ann Taylor, LOFT, Lou & Grey, and Lane Bryant brands to Premium Apparel LLC, an affiliate of Sycamore Partners. Premium Apparel has committed to retaining a substantial portion of the retail stores, associates, and corporate operations affiliated with these brands.“We are pleased to have completed this transaction, which secures a path for the long-term success of Ann Taylor, LOFT, Lou & Grey, and Lane Bryant,” said Gary Muto, Chief Executive Officer. “We have worked diligently to maximize the value of our brands, and we are confident they will thrive under...

CARROLLTON, Texas, Dec. 23, 2020 (GLOBE NEWSWIRE) — ADDvantage Technologies Group, Inc. (NASDAQ: AEY) (“ADDvantage Technologies” or the “Company”) today announced that Michael Burch has been promoted to Vice President of Network Solutions at Nave Communications.“This promotion recognizes the tremendous value Mike has added to our customers and Nave Communications over his 16-year tenure,” commented Reggie Jaramillo, President of the Telecommunications segment. “Mike has worked with our customers to develop network solutions and to provide equipment and services that enhance the customer experience. His knowledge of networks and creative thinking allow Mike to provide value adding and cost-effective solutions.”Mr. Burch began his career with Nave Communications in 2004 serving as an assistant to the VP of Sales. He subsequently learned...

PLEASANTON, Calif., Dec. 23, 2020 (GLOBE NEWSWIRE) — 10x Genomics (Nasdaq: TXG) today announced the company will be participating in the upcoming 39th Annual J.P. Morgan Virtual Healthcare Conference.10x Genomics’ management is scheduled to present on Monday, January 11 at 7:00 a.m. Pacific Time / 10:00 a.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation on the “Investors” section of the company website at: investors.10xgenomics.comAbout 10x Genomics10x Genomics is a life science technology company building products to interrogate, understand and master biology to advance human health. The company’s integrated solutions include instruments, consumables and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. 10x Genomics products...

BOSTON, Dec. 23, 2020 (GLOBE NEWSWIRE) — Ziopharm Oncology, Inc. (“Ziopharm” or “the Company”) (Nasdaq: ZIOP), today announced that Laurence Cooper, M.D., Ph.D., Chief Executive Officer of Ziopharm, is scheduled to participate in a fireside chat at the H.C. Wainwright Bioconnect 2021 Conference and will deliver a corporate overview at the 39th Annual J.P. Morgan Healthcare Conference.To access the webcast presentations, or the subsequent archived recordings, please visit the “Investors” section of the Ziopharm website at www.ziopharm.com.About Ziopharm Oncology, Inc.Ziopharm is developing non-viral and cytokine-driven cell and gene therapies that weaponize the body’s immune system to treat the millions of people globally diagnosed with a solid tumor each year. With its multiplatform approach, Ziopharm is at the forefront of immuno-oncology...

CALGARY, Alberta, Dec. 23, 2020 (GLOBE NEWSWIRE) — Gibson Energy Inc. announced today that it has completed the previously announced redemption of its outstanding 5.25% convertible unsecured debentures due July 15, 2021 (the “Debentures”).The redemption terms were in accordance with the provisions of the trust indenture governing the Debentures, and were as follows:The aggregate outstanding principal amount of the Debentures was $99.3 million on the date of Gibson’s redemption announcement on November 20, 2020. Pursuant to the conversion option available to holders of the Debentures, an aggregate of 134,916 common shares were issued in relation to conversion requests received by Gibson between the date of its redemption announcement and December 23, 2020. The remaining outstanding principal amount of Debentures was redeemed on the...

WEST CHESTER, Pa., Dec. 23, 2020 (GLOBE NEWSWIRE) — Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that it has resubmitted the New Drug Application (NDA) for VP-102 for the treatment of molluscum contagiosum (molluscum) to the U.S. Food and Drug Administration (FDA). The NDA for VP-102 was resubmitted based on the outcome and final minutes of a Type A meeting with the FDA, which was conducted to obtain clarity on the Complete Response Letter (CRL) issued by the FDA in July 2020. “We are pleased that we were able to expeditiously provide a comprehensive resubmission of the NDA focused on the Chemistry, Manufacturing and Controls (CMC) information as well as Human Factors validation identified by the...